Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 1.24
EBS's Cash to Debt is ranked lower than
78% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. EBS: 1.24 )
Ranked among companies with meaningful Cash to Debt only.
EBS' s Cash to Debt Range Over the Past 10 Years
Min: 0.53  Med: 2.26 Max: No Debt
Current: 1.24
Equity to Asset 0.63
EBS's Equity to Asset is ranked lower than
57% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. EBS: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
EBS' s Equity to Asset Range Over the Past 10 Years
Min: -1.27  Med: 0.63 Max: 0.78
Current: 0.63
-1.27
0.78
Interest Coverage 14.72
EBS's Interest Coverage is ranked lower than
79% of the 393 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. EBS: 14.72 )
Ranked among companies with meaningful Interest Coverage only.
EBS' s Interest Coverage Range Over the Past 10 Years
Min: 7.05  Med: 2815.62 Max: N/A
Current: 14.72
F-Score: 6
Z-Score: 4.29
M-Score: -1.23
WACC vs ROIC
9.13%
11.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 18.37
EBS's Operating margin (%) is ranked higher than
84% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -66.05 vs. EBS: 18.37 )
Ranked among companies with meaningful Operating margin (%) only.
EBS' s Operating margin (%) Range Over the Past 10 Years
Min: 10.63  Med: 16.93 Max: 25.7
Current: 18.37
10.63
25.7
Net-margin (%) 12.03
EBS's Net-margin (%) is ranked higher than
80% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -68.08 vs. EBS: 12.03 )
Ranked among companies with meaningful Net-margin (%) only.
EBS' s Net-margin (%) Range Over the Past 10 Years
Min: 8.16  Med: 11.81 Max: 18.07
Current: 12.03
8.16
18.07
ROE (%) 10.77
EBS's ROE (%) is ranked higher than
85% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. EBS: 10.77 )
Ranked among companies with meaningful ROE (%) only.
EBS' s ROE (%) Range Over the Past 10 Years
Min: 5.5  Med: 10.76 Max: 23
Current: 10.77
5.5
23
ROA (%) 6.52
EBS's ROA (%) is ranked higher than
86% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. EBS: 6.52 )
Ranked among companies with meaningful ROA (%) only.
EBS' s ROA (%) Range Over the Past 10 Years
Min: 4.23  Med: 6.84 Max: 13.46
Current: 6.52
4.23
13.46
ROC (Joel Greenblatt) (%) 22.79
EBS's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. EBS: 22.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EBS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 11.5  Med: 23.73 Max: 61.78
Current: 22.79
11.5
61.78
Revenue Growth (3Y)(%) 12.60
EBS's Revenue Growth (3Y)(%) is ranked higher than
64% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. EBS: 12.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EBS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.1  Med: 10.90 Max: 31.3
Current: 12.6
-1.1
31.3
EBITDA Growth (3Y)(%) 32.80
EBS's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 497 Companies
in the Global Biotechnology industry.

( Industry Median: -0.30 vs. EBS: 32.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EBS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -2.10 Max: 32.8
Current: 32.8
0
32.8
EPS Growth (3Y)(%) 27.20
EBS's EPS Growth (3Y)(%) is ranked higher than
81% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. EBS: 27.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EBS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -26.5  Med: 2.30 Max: 61.6
Current: 27.2
-26.5
61.6
» EBS's 10-Y Financials

Financials (Next Earnings Date: 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

EBS Guru Trades in Q2 2015

Paul Tudor Jones 15,300 sh (+20.55%)
Jim Simons 671,511 sh (+14.43%)
Ken Fisher 462,428 sh (-7.78%)
» More
Q3 2015

EBS Guru Trades in Q3 2015

Paul Tudor Jones 32,366 sh (+111.54%)
Jim Simons 774,211 sh (+15.29%)
Ken Fisher 458,634 sh (-0.82%)
» More
Q4 2015

EBS Guru Trades in Q4 2015

Joel Greenblatt 446,867 sh (New)
Jim Simons 951,611 sh (+22.91%)
Ken Fisher 457,742 sh (-0.19%)
Paul Tudor Jones 26,796 sh (-17.21%)
» More
Q1 2016

EBS Guru Trades in Q1 2016

Ken Fisher 457,742 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with EBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 31.31
EBS's P/E(ttm) is ranked lower than
53% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 30.50 vs. EBS: 31.31 )
Ranked among companies with meaningful P/E(ttm) only.
EBS' s P/E(ttm) Range Over the Past 10 Years
Min: 6.72  Med: 22.05 Max: 71.97
Current: 31.31
6.72
71.97
Forward P/E 14.37
EBS's Forward P/E is ranked higher than
61% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 17.92 vs. EBS: 14.37 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 32.38
EBS's PE(NRI) is ranked lower than
53% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 31.00 vs. EBS: 32.38 )
Ranked among companies with meaningful PE(NRI) only.
EBS' s PE(NRI) Range Over the Past 10 Years
Min: 6.69  Med: 22.17 Max: 71.14
Current: 32.38
6.69
71.14
Price/Owner Earnings (ttm) 192.60
EBS's Price/Owner Earnings (ttm) is ranked lower than
89% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 33.75 vs. EBS: 192.60 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
EBS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.87  Med: 30.23 Max: 639.68
Current: 192.6
5.87
639.68
P/B 2.32
EBS's P/B is ranked higher than
66% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. EBS: 2.32 )
Ranked among companies with meaningful P/B only.
EBS' s P/B Range Over the Past 10 Years
Min: 0.84  Med: 1.87 Max: 3.82
Current: 2.32
0.84
3.82
P/S 3.44
EBS's P/S is ranked higher than
78% of the 674 Companies
in the Global Biotechnology industry.

( Industry Median: 11.42 vs. EBS: 3.44 )
Ranked among companies with meaningful P/S only.
EBS' s P/S Range Over the Past 10 Years
Min: 0.75  Med: 2.25 Max: 4.31
Current: 3.44
0.75
4.31
POCF 67.15
EBS's POCF is ranked lower than
83% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 25.07 vs. EBS: 67.15 )
Ranked among companies with meaningful POCF only.
EBS' s POCF Range Over the Past 10 Years
Min: 2.59  Med: 14.07 Max: 108.3
Current: 67.15
2.59
108.3
EV-to-EBIT 15.20
EBS's EV-to-EBIT is ranked higher than
61% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.70 vs. EBS: 15.20 )
Ranked among companies with meaningful EV-to-EBIT only.
EBS' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.8  Med: 14.50 Max: 40.4
Current: 15.2
1.8
40.4
EV-to-EBITDA 11.99
EBS's EV-to-EBITDA is ranked higher than
64% of the 275 Companies
in the Global Biotechnology industry.

( Industry Median: 20.64 vs. EBS: 11.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
EBS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.7  Med: 10.80 Max: 23.4
Current: 11.99
1.7
23.4
PEG 4.16
EBS's PEG is ranked lower than
67% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.23 vs. EBS: 4.16 )
Ranked among companies with meaningful PEG only.
EBS' s PEG Range Over the Past 10 Years
Min: 0.86  Med: 8.62 Max: 90.05
Current: 4.16
0.86
90.05
Shiller P/E 41.72
EBS's Shiller P/E is ranked higher than
61% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.88 vs. EBS: 41.72 )
Ranked among companies with meaningful Shiller P/E only.
EBS' s Shiller P/E Range Over the Past 10 Years
Min: 16.78  Med: 32.00 Max: 44.11
Current: 41.72
16.78
44.11
Current Ratio 5.41
EBS's Current Ratio is ranked higher than
55% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. EBS: 5.41 )
Ranked among companies with meaningful Current Ratio only.
EBS' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 3.38 Max: 5.41
Current: 5.41
1.22
5.41
Quick Ratio 4.63
EBS's Quick Ratio is ranked higher than
51% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. EBS: 4.63 )
Ranked among companies with meaningful Quick Ratio only.
EBS' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 3.18 Max: 4.63
Current: 4.63
0.83
4.63
Days Inventory 228.77
EBS's Days Inventory is ranked lower than
78% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 120.79 vs. EBS: 228.77 )
Ranked among companies with meaningful Days Inventory only.
EBS' s Days Inventory Range Over the Past 10 Years
Min: 87.55  Med: 124.71 Max: 311.38
Current: 228.77
87.55
311.38
Days Sales Outstanding 71.32
EBS's Days Sales Outstanding is ranked lower than
55% of the 603 Companies
in the Global Biotechnology industry.

( Industry Median: 66.24 vs. EBS: 71.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
EBS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 32.39  Med: 62.36 Max: 124.36
Current: 71.32
32.39
124.36
Days Payable 134.98
EBS's Days Payable is ranked higher than
73% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 63.23 vs. EBS: 134.98 )
Ranked among companies with meaningful Days Payable only.
EBS' s Days Payable Range Over the Past 10 Years
Min: 126.17  Med: 179.15 Max: 414.03
Current: 134.98
126.17
414.03

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 9.80
EBS's Price/Net Current Asset Value is ranked lower than
67% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.40 vs. EBS: 9.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EBS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.59  Med: 6.34 Max: 21.96
Current: 9.8
3.59
21.96
Price/Tangible Book 3.00
EBS's Price/Tangible Book is ranked higher than
62% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. EBS: 3.00 )
Ranked among companies with meaningful Price/Tangible Book only.
EBS' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.88  Med: 2.16 Max: 3.92
Current: 3
0.88
3.92
Price/Projected FCF 2.19
EBS's Price/Projected FCF is ranked higher than
67% of the 172 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. EBS: 2.19 )
Ranked among companies with meaningful Price/Projected FCF only.
EBS' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.54  Med: 1.77 Max: 2.32
Current: 2.19
1.54
2.32
Price/DCF (Earnings Based) 3.03
EBS's Price/DCF (Earnings Based) is ranked lower than
83% of the 18 Companies
in the Global Biotechnology industry.

( Industry Median: 1.16 vs. EBS: 3.03 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.51
EBS's Price/Median PS Value is ranked lower than
76% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. EBS: 1.51 )
Ranked among companies with meaningful Price/Median PS Value only.
EBS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 1.07 Max: 1.97
Current: 1.51
0.36
1.97
Price/Peter Lynch Fair Value 3.39
EBS's Price/Peter Lynch Fair Value is ranked lower than
72% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 1.87 vs. EBS: 3.39 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
EBS' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.6  Med: 2.23 Max: 10.24
Current: 3.39
0.6
10.24
Price/Graham Number 2.08
EBS's Price/Graham Number is ranked higher than
54% of the 292 Companies
in the Global Biotechnology industry.

( Industry Median: 2.51 vs. EBS: 2.08 )
Ranked among companies with meaningful Price/Graham Number only.
EBS' s Price/Graham Number Range Over the Past 10 Years
Min: 0.51  Med: 1.32 Max: 2.59
Current: 2.08
0.51
2.59
Earnings Yield (Greenblatt) (%) 6.58
EBS's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. EBS: 6.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EBS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.5  Med: 6.90 Max: 54.3
Current: 6.58
2.5
54.3
Forward Rate of Return (Yacktman) (%) 10.27
EBS's Forward Rate of Return (Yacktman) (%) is ranked lower than
57% of the 107 Companies
in the Global Biotechnology industry.

( Industry Median: 14.45 vs. EBS: 10.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
EBS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -13.6  Med: 1.00 Max: 14.4
Current: 10.27
-13.6
14.4

More Statistics

Revenue(Mil) $523
EPS $ 1.23
Beta1.12
Short Percentage of Float9.87%
52-Week Range $27.68 - 40.96
Shares Outstanding(Mil)39.47

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 608 729
EPS($) 2.01 2.68
EPS without NRI($) 2.01 2.68

Business Description

Industry: Biotechnology » Biotechnology
Compare:SZSE:300294, SHSE:600161, NAS:NKTR, SZSE:300009, HKSE:00570, ROCO:4174 » details
Traded in other countries:ER4.Germany,
Emergent BioSolutions Inc was incorporated as BioPort Corporation under the laws of Michigan in May 1998 and subsequently reorganized as a Delaware corporation in June 2004. The Company is a biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body's immune system to prevent or treat disease. It develops vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism and biowarfare and infectious diseases that have resulted in significant unmet or underserved public health needs. The Company manufactures and markets BioThrax(r), also referred to as anthrax vaccine adsorbed, the only vaccine approved by the U.S. Food and Drug Administration, or FDA, for the prevention of anthrax infection. BioThrax is approved for pre-exposure prevention of anthrax infection by all routes of exposure, including inhalation. The Company operates in two business segments, biodefense and biosciences. Its biodefense segment focuses on vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism or biowarfare. Its product candidates in this segment are focused on two specific biological agents: anthrax and botulinum. Within its anthrax product portfolio, the Company manufactures and markets BioThrax(r) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. In addition to BioThrax, the Company is developing a recombinant protective antigen anthrax, or rPA, vaccine an advanced BioThrax vaccine, an anthrax immune globulin therapeutic and a recombinant anthrax monoclonal antibody therapeutic. Within its botulinum product portfolio, it is developing a recombinant botulinum vaccine. The Company's Biosciences division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation and infectious disease. The Company's products and any product or product candidate that it acquires or successfully develop and commercialize is likely to compete with currently marketed products, such as vaccines, antibody therapies, antibiotics and other product candidates that are in development for the same indications. Specifically, the competition for its products and product candidates includes BioThrax, RSDL, BAT, AIGIV, VIGIV and PreviThrax and NuThrax. Accordingly, it is subject to federal, state, local and foreign laws and regulations governing the use, manufacture, distribution, storage, handling, disposal and recordkeeping of these materials.
» More Articles for EBS

Headlines

Articles On GuruFocus.com
Weekly CEO Sales Highlight: Realpage, Anadigics, Emergent BioSolutions, ScanSource Jan 03 2016 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Nov 05 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Aug 06 2010 
Emergent BioSolutions Inc. (EBS) President & COO Daniel Abdun-nabi sells 18,150 Shares Jul 30 2010 
Weekly CEO Sells Highlight: Yum! Brands Inc, Marchex Inc, iGate Corp, and Emergent BioSolutions Inc. Jul 25 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 18,800 Shares Jul 23 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 130,100 Shares Jul 22 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 84,433 Shares Jul 19 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 52,000 Shares May 14 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) May 06 2010 

More From Other Websites
5 Sturdy Stocks to Play Weakest Growth in 2 Years Apr 29 2016
Erste Bank Sells Interests in Hotels Apr 28 2016
Opening: Erste Advisory Center in Sievering, Vienna Apr 28 2016
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Molina Healthcare, PAREXEL International,... Apr 27 2016
Erste Bank: New Head of Retail Austria Division Apr 27 2016
Emergent Biosolutions to Participate in the Bank of America Merrill Lynch Healthcare Conference in... Apr 26 2016
Emergent Biosolutions to Participate in the Bank of America Merrill Lynch Healthcare Conference in... Apr 26 2016
5 Stocks to Invest on Healthcare Rebound Apr 26 2016
Top 5 Stocks with Increasing Cash Flows Apr 25 2016
Emergent BioSolutions to Release First Quarter 2016 Financial Results and Conduct a Conference Call... Apr 21 2016
Emergent BioSolutions to Release First Quarter 2016 Financial Results and Conduct a Conference Call... Apr 21 2016
Evolent Health awards executive bonuses following debut on NYSE Apr 21 2016
Erste Bank und Sparkassen Group posts operating earnings of EUR 864.6 m. Apr 21 2016
Evolent Health awards executive bonuses following debut on Nasdaq Apr 21 2016
Wizz Air is newest major tenant in Erste Group Immorent’s Laurus Offices in Budapest Apr 21 2016
Emergent BioSolutions Presents Preclinical Data on ES425 a Bispecific Immunotherapeutic Protein for... Apr 20 2016
Emergent BioSolutions Presents Preclinical Data on ES425 a Bispecific Immunotherapeutic Protein for... Apr 20 2016
Erste Group and Austrian savings banks to tender their media account Apr 19 2016
Emergent Biosolutions Reveals sBLA Submission To FDA To Make BioThrax In Building 55 Apr 18 2016
Emergent BioSolutions Submits sBLA for FDA Approval of Large-Scale Manufacturing of BioThrax in... Apr 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK